1. Home
  2. SAFE vs ARDX Comparison

SAFE vs ARDX Comparison

Compare SAFE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

SELL

Current Price

$12.01

Market Cap

842.7M

Sector

Real Estate

ML Signal

SELL

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

SELL

Current Price

$3.11

Market Cap

862.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SAFE
ARDX
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.7M
862.3M
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
SAFE
ARDX
Price
$12.01
$3.11
Analyst Decision
Hold
Strong Buy
Analyst Count
11
11
Target Price
★ $17.60
$12.90
AVG Volume (30 Days)
621.7K
★ 4.1M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
★ 5.87%
N/A
EPS Growth
★ 7.43
N/A
EPS
★ 0.82
N/A
Revenue
★ $385,552,000.00
$2,607,000.00
Revenue This Year
$12.09
$19.98
Revenue Next Year
$4.69
$27.70
P/E Ratio
$14.71
★ N/A
Revenue Growth
★ 5.43
N/A
52 Week Low
$11.60
$3.18
52 Week High
$17.45
$8.40

Technical Indicators

Market Signals
Indicator
SAFE
ARDX
Relative Strength Index (RSI) 29.47 26.15
Support Level $11.60 N/A
Resistance Level $16.43 $3.63
Average True Range (ATR) 0.30 0.10
MACD 0.08 0.01
Stochastic Oscillator 33.07 8.33

Price Performance

Historical Comparison
SAFE
ARDX

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: